

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol-Myers Squibb	Grant / Contract	Self
Recipient Name: Charalambos Andreadis Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Epizyme, Inc.,	Consultant	Self
Category: Consultant Additional Information:		Description:
Genentech	Employment	Spouse/Partner
Title: research scientist Additional Information: ended 2/18/2020		Position Description:
Incyte Corporation	Consultant	Self
Category: Consultant Additional Information:		Description:
Karyopharm Therapeutics	Consultant	Self
Category: Consultant Additional Information:		Description:
Kite Pharma, Inc.	Consultant	Self
Category: Consultant Additional Information:		Description:
Merck	Grant / Contract	Self
Recipient Name: Charalambos Andreadis Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Novartis	Grant / Contract	Self
Recipient Name: Charalambos Andreadis Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose:
TG therapeutics	Consultant	Self
Category: Consultant Additional Information:		Description:

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Employment	Self
Title: Clinical Development Medical Director		Position Description: Clinical study medical directo
Additional Information:		
Novartis	Stock Option	Self
Additional Information:		

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis Pharmaceuticals Corporation	Employment	Self
Title: Principal Scientist Additional Information:		Position Description:

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Travel	Self
Location(s): San Diego Additional Information:		Purpose: Congress
Amgen	Grant / Contract	Self
Recipient Name: IRCCS Grant / Contract Description: Research grant Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Celgene	Other	Self
Category: Other Additional Information:		Description: Scientific Advisory Board
Incyte Corporation	Other	Self
Category: Other Additional Information:		Description: Speaking engagement
Incyte Corporation	Other	Self
Category: Other Additional Information:		Description: Scientific Advisory Board
Incyte Corporation	Travel	Self
Location(s): Paris Additional Information:		Purpose: Congress
Kite Pharma, Inc.	Other	Self
Category: Other Additional Information:		Description: Scientific Advisory Board
Novartis	Other	Self
Category: Other Additional Information:		Description: Speaking engagement

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol-Myers Squibb	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory boards
Bristol-Myers Squibb	Travel	Self
Location(s): several in Europe and US Additional Information:		Purpose: hematology meetings, ASH, SEHH,EHA
Kite Pharma, Inc.	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory board
Kite Pharma, Inc.	Travel	Self
Location(s): several in Europe and US Additional Information:		Purpose: hematology meetings, ASH, SEHH,EHA
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description: advisory boards
Novartis	Travel	Self
Location(s): several in Europe and US Additional Information:		Purpose: hematology meetings, ASH, SEHH,EHA

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol Myers Squibb Company	Consultant	Self
Category: Consultant Additional Information: Also participate in speakers bureau outside this work		Description: Advisory Boards
CRISPR Therapeutics	Consultant	Self
Category: Consultant Additional Information: Also serve as clinical investigator and steering committee for clinical trials		Description:
Kite Pharma, Inc.	Consultant	Self
Category: Consultant Additional Information: Serve as clinical investigator on clinical trials and participate on company-sponsored speakers bureau		Description: Advisory boards
Novartis	Consultant	Self
Category: Consultant Additional Information: Serve as investigator and steering committees for clinical trials		Description: Advisory boards
Sana Biotechnology	Consultant	Self
Category: Consultant Additional Information:		Description:

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
Yes.

a. Please list the other authors' names here.
Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian Flinn, Werner Rabitsch, Yok Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquin Martinez-Lopez, Antonia M.S. Mueller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David Bond, Charalambos Andreadis, Peter McSweeney, Mohamed Kharfan-Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jaeger, Peter Borchmann, Jason R. Westin

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Kite Pharma, Inc.	Other	Self
Category: Other Additional Information:		Description: Scientific advisory board
Seagen Inc.	Other	Self
Category: Other Additional Information:		Description: Scientific advisory board

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description:

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Other	Self
Category: Other Additional Information:		Description: Ad board/talks
Novartis	Other	Self
Category: Other Additional Information:		Description: Speaking engagement/Ad Board

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2. What is the manuscript title?

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Employment	Self
Title: Director Additional Information:		Position Description: Biostatistics
Novartis	Stock	Self
Additional Information:		

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Employment	Self
Title: Associate Clinical Development Director Additional Information:		Position Description: Responsible for scientific and clinical strategy related to drug development
Novartis	Stock	Self
Additional Information:		

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol-Myers Squibb	Grant / Contract	Other - Employing Institution
Recipient Name: Michael Dickinson Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Bristol-Myers Squibb	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board
Gilead Sciences	Grant / Contract	Other - Employing institution
Recipient Name: Peter MacCallum Cancer Centre Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Novartis	Grant / Contract	Other - Hospital
Recipient Name: Peter MacCallum Cancer Centre Grant / Contract Description: Research Funding Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description:
Novartis	Other	Self
Category: Other Additional Information:		Description: Advisory Board
Roche	Grant / Contract	Other - Employing organisation
Recipient Name: Peter MacCallum Cancer Centre Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Roche	Consultant	Self
Category: Consultant Additional Information:		Description:

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Grant / Contract	Self
Recipient Name: Martin Dreyling Grant / Contract Description: clinical study Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Amgen	Grant / Contract	Self
Recipient Name: Martin Dreyling Grant / Contract Description: speaker honoraria Additional Information:		Recipient Type: Individual Grant / Contract Purpose: Other - speaker honoraria
AstraZeneca	Consultant	Self
Category: Consultant Additional Information:		Description: scientific advisory board
Bayer	Grant / Contract	Self
Recipient Name: Martin Dreyling Grant / Contract Description: clinical trial Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Bayer	Other	Self
Category: Other Additional Information:		Description: speaker honoraria
Bayer	Consultant	Self
Category: Consultant Additional Information:		Description: scientific advisory board
BeiGene Switzerland GmbH	Consultant	Self
Category: Consultant Additional Information:		Description: scientif advisory board
Bristol-Myers Squibb	Grant / Contract	Self
Recipient Name: Martin Dreyling Grant / Contract Description: clinical study Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Bristol-Myers Squibb	Consultant	Self
Category: Consultant Additional Information:		Description: scientific advisory board
Bristol-Myers Squibb	Other	Self
Category: Other Additional Information:		Description: speaker honoraria
Eli Lilly and Company	Consultant	Self
Category: Consultant Additional Information:		Description: scientific advisory board
F. Hoffmann-La Roche	Grant / Contract	Self
Recipient Name: Martin Dreyling Grant / Contract Description: clinical study Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
F. Hoffmann-La Roche	Consultant	Self
Category: Consultant Additional Information:		Description: scientific advisory board

F. Hoffmann-La Roche	Other	Self
Category: Other Additional Information:		Description: speaker honoraria
Gilead Sciences	Grant / Contract	Self
Recipient Name: Martin Dreyling Grant / Contract Description: clinical study Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Gilead Sciences	Other	Self
Category: Other Additional Information:		Description: scientific advisory board
Gilead Sciences	Other	Self
Category: Other Additional Information:		Description: Speaker honoraria
Incyte Corporation	Other	Self
Category: Other Additional Information:		Description: speaker honoraria
Incyte Corporation	Consultant	Self
Category: Consultant Additional Information:		Description: scientific advisory board
Janssen Biotech	Grant / Contract	Self
Recipient Name: Martin Dreyling Grant / Contract Description: clinical study Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Janssen Biotech	Other	Self
Category: Other Additional Information:		Description: speaker honoraria
Janssen Biotech	Consultant	Self
Category: Consultant Additional Information:		Description: scientific advisory board
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description: scientific advisory board
Novartis	Other	Self
Category: Other Additional Information:		Description: speaker honoraria

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma

3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
AbbVie	Consultant	Self
Category: Consultant Additional Information: Consulting paid to institution, Sarah Cannon Research Institute		Description: CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAID TO INSTITUTION
ACERTA PHARMACEUTICALS	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Agios Pharmaceuticals, Inc.	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
ARQLE	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
AstraZeneca	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
AstraZeneca	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician
BEIGENE	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
BEIGENE	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician
Calithera Biosciences	Grant / Contract	Self
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician		Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician
Celgene	Grant / Contract	Self
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Century Therapeutics	Consultant	Self
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician

Constellation Pharmaceuticals	Grant / Contract	Self
<i>Recipient Name:</i> Sarah Cannon Research Institute <i>Grant / Contract Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician <i>Additional Information:</i>		
CURIS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
F. HOFMAN-LA ROCHE LTD	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
F. HOFMAN-LA ROCHE LTD	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulting payment made to institution, Sarah Cannon Research Institute		
FORMATHERAPEUTICS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
FORTY SEVEN	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
Genentech	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
Genentech	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Genmab	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Gilead Sciences	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
Gilead Sciences	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulting payment made to institution, Sarah Cannon Research Institute		
Great Point Partners	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Hutchison MediPharma	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
IGM Biosciences	Grant / Contract	Self
<i>Recipient Name:</i> Sarah Cannon Research Institute <i>Grant / Contract Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician <i>Additional Information:</i>		
Iksuda Therapeutics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Incyte Corporation	Grant / Contract	Self

Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
INFINITY PHARMACEUTICALS	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
InnoCare Pharma	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Janssen Biotech	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
Janssen Biotech	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Juno Therapeutics	Grant / Contract	Self	
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician		Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	
Juno Therapeutics	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Karyopharm Therapeutics	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
KITE	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
KITE	Consultant	Self	
Category: Consultant Additional Information: Consulting payment made to institution, Sarah Cannon Research Institute		Description: CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAID TO INSTITUTION	
Loxo	Grant / Contract	Self	
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician		Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	
Merck	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
MORHOSYS	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
MorphoSys	Grant / Contract	Self	
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician		Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	
MorphoSys	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Novartis	Grant / Contract	Self	

Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
Novartis	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Nurix Therapeutics	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Pfizer	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
Pharmacyclics LLC, An AbbVie Company	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
Pharmacyclics LLC, An AbbVie Company	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Portola Pharmaceuticals	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
Rhizen Pharmaceuticals	Grant / Contract	Self	
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician		Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	
Roche	Grant / Contract	Self	
Recipient Name: Sarah Cannon Research Institute Grant / Contract Description: All payments made to Sarah Cannon Research Institute, not to the physician		Recipient Type: Institution Grant / Contract Purpose: Research Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician	
Roche	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Seattle Genetics	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
Seattle Genetics	Consultant	Self	
Category: Consultant Additional Information: Consulting payment made to institution, Sarah Cannon Research Institute		Description: CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAID TO INSTITUTION	
Servier Pharmaceuticals LLC	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Takeda Oncology	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	
Takeda Oncology	Consultant	Self	
Category: Consultant Additional Information: All payments made to Sarah Cannon Research Institute, not to the physician		Description: All payments made to Sarah Cannon Research Institute, not to the physician	
Teva Pharmaceuticals USA, Inc.	Grant / Contract	Self	
Recipient Name: SARAH CANNON RESEARCH INSTITUTE Grant / Contract Description: RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research	

TG THERAPEUTICS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
TG THERAPEUTICS	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulting payment made to institution, Sarah Cannon Research Institute		
<i>Description:</i> CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAID TO INSTITUTION		
TRILLIUM THERAPEUTICS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Triphase Research & Development Corp.	Grant / Contract	Self
<i>Recipient Name:</i> Sarah Cannon Research Institute <i>Grant / Contract Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
UNUM THERAPEUTICS	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
UNUM THERAPEUTICS	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
VERASTEM	Grant / Contract	Self
<i>Recipient Name:</i> SARAH CANNON RESEARCH INSTITUTE <i>Grant / Contract Description:</i> RESEARCH FUNDING TO SARAH CANNON RESEARCH INSTITUTE <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
VERASTEM	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulting payment made to institution, Sarah Cannon Research Institute		
<i>Description:</i> CONSULTANCY: ADVISORY BOARD OR STEERING COMMITTEE PAYMENT MADE TO INSTITUTION		
Vincerox Pharma	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
Yingli Pharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> All payments made to Sarah Cannon Research Institute, not to the physician		
<i>Description:</i> All payments made to Sarah Cannon Research Institute, not to the physician		

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Amgen	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
AstraZeneca	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Bristol-Myers Squibb	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Celgene	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Celgene	Consultant	Self
Category: Consultant Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Daiichi Sankyo Company	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
F. Hoffmann-La Roche	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Gilead Sciences	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Merck	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Merck Sharp and Dohme	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Novartis	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Sandoz Inc.	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	
Takeda Oncology	Other	Self
Category: Other Additional Information:	Description: Honoraria, Consulting Adv Role, Research Funding, Travel, Accomodations, Expenses	

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Consultant	Self
Category: Consultant Additional Information: Advisory Board		Description: Advisory Board

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AsahiKasei Medical Co.,Ltd.	Grant / Contract	Self
Recipient Name: Tohoku University Grant / Contract Description: Additional Information:Recipient Type: Institution Grant / Contract Purpose: Research		
Bristol-Myers Squibb	Other	Self
Category: Other Additional Information:Description: speaking engagement		
Chugai Pharmaceutical	Other	Self
Category: Other Additional Information:Description: speaking engagement		
Chugai Pharmaceutical Co., Ltd.	Grant / Contract	Self
Recipient Name: Tohoku University Grant / Contract Description: Additional Information:Recipient Type: Institution Grant / Contract Purpose: Research		
Eisai Co., Ltd.	Grant / Contract	Self
Recipient Name: Tohoku University Grant / Contract Description: Additional Information:Recipient Type: Institution Grant / Contract Purpose: Research		
Kyowa Kirin Co., Ltd	Grant / Contract	Self
Recipient Name: Tohoku University Grant / Contract Description: Additional Information:Recipient Type: Institution Grant / Contract Purpose: Research		
Novartis	Other	Self
Category: Other Additional Information:Description: speaking engagement		
Sanofi	Other	Self
Category: Other Additional Information:Description: speaking engagement		
Takeda Pharmaceutical Company, Limited	Grant / Contract	Self
Recipient Name: Tohoku University Grant / Contract Description: Additional Information:Recipient Type: Institution Grant / Contract Purpose: Research		

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2.

What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Genmab	Data And Safety Monitoring	Other - Honoraria to my institution
Category: Data And Safety Monitoring Additional Information:		Description: Safety Committee
Gilead Sciences	Consultant	Self
Category: Consultant Additional Information: Honoraria to my institution		Description:
Incyte Corporation	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board. Evaluation Committe for grant application
Nordic Nanovector	Data And Safety Monitoring	Other - Honoraria to my institution
Category: Data And Safety Monitoring Additional Information:		Description: Safety Committee
Novartis	Other	Self
Category: Other Additional Information:		Description: Invited lecturer paid by Novartis, Advisory board
Roche Health Solutions Inc.	Consultant	Other - Honoraria to my institution
Category: Consultant Additional Information:		Description: Advisory Board
Takeda Oncology	Consultant	Other - Honoraria to my institution
Category: Consultant Additional Information:		Description: Advisory Board

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Efficacy and Safety of Tisagenlecleucel Versus Standard of Care in Adult Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol Myers Squibb Company	Consultant	Self
Category: Consultant Additional Information:	Description: CAR-T cell therapy advice	
Gilead Sciences	Other	Self
Category: Other Additional Information:	Description: Advisory Board	
Janssen Global Services, LLC	Consultant	Self
Category: Consultant Additional Information:	Description: CAR-T cells and CLL, Myeloma	
Miltenyi Biotec	Other	Self
Category: Other Additional Information:	Description: Advisory Board	
Novartis	Consultant	Self
Category: Consultant Additional Information:	Description: Consultant for CAR-T Cell Development	

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences	Travel	Self
Location(s): Additional Information:		Purpose:
Janssen Biotech	Other	Self
Category: Other Additional Information:		Description: Scientific Advisory Board
Janssen Biotech	Travel	Self
Location(s): Additional Information:		Purpose:
Novartis	Other	Self
Category: Other Additional Information:		Description: Scientific Advisory Board
Takeda Oncology	Other	Self
Category: Other Additional Information:		Description: Scientific Advisory Board
Takeda Oncology	Travel	Self
Location(s): Additional Information:		Purpose:

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Grant / Contract	Other - Kyushu University
Recipient Name: Koji Kato Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
AstraZeneca	Grant / Contract	Other - Kyushu University
Recipient Name: Koji Kato Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Bristol-Myers Squibb	Grant / Contract	Other - Kyushu University
Recipient Name: Koji Kato Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Chugai Pharmaceutical Co., Ltd.	Grant / Contract	Other - Kyushu University
Recipient Name: Koji Kato Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Daiichi Sankyo Company LTD	Grant / Contract	Other - Kyushu University
Recipient Name: Koji Kato Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Eisai Co., Ltd.	Grant / Contract	Other - Kyushu University
Recipient Name: Koji Kato Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Kyowa Kirin Co., Ltd	Grant / Contract	Other - Kyushu University
Recipient Name: Koji Kato Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Novartis	Grant / Contract	Other - Kyushu University
Recipient Name: Koji Kato Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Ono	Grant / Contract	Other - Kyushu University
Recipient Name: Koji Kato Grant / Contract Description: Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol Myers Squibb Company	Other	Self
Category: Other Additional Information:		Description: Compensation for presentation Paid to Institution
Celgene	Other	Self
Category: Other Additional Information: to institution		Description: Scientific Advisory Board
F. Hoffmann-La Roche	Other	Self
Category: Other Additional Information: educational symposium		Description: Speaker fee
Kite Pharma	Grant / Contract	Self
Recipient Name: Amsterdam UMC Grant / Contract Description: Research grant Additional Information:		Recipient Type: Institution Grant / Contract Purpose: Research
Kite Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: advisory board
Kite Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: advisory board
Kite Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: speaker fee educational symposium
Kite Pharma	Other	Self
Category: Other Additional Information:		Description: travel reimbursement investigator meeting
Kite Pharma	Other	Self
Category: Other Additional Information:		Description: Speaker fee
Kite Pharma	Other	Self
Category: Other Additional Information:		Description: speaker fee educational symposium
Kite Pharma	Other	Self
Category: Other Additional Information:		Description: Advisory Board
Kite Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: speaker fee educational symposium
Kite Pharma	Consultant	Other - fee paid to institution
Category: Consultant Additional Information:		Description: advisory board
Kite Pharma	Consultant	Self
Category: Consultant		Description: advisory board

Additional Information:		
Kite Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: speaker fee
Kite Pharma	Consultant	Other - fee paid to institution
Category: Consultant Additional Information:		Description: advisory board
Kite Pharma	Consultant	Self
Category: Consultant Additional Information: advisory board		Description: advisory board
Kite Pharma	Travel	Self
Location(s): New York Additional Information:		Purpose: Advisory Board
Miltenyi Biotec	Consultant	Other - fee paid to institution
Category: Consultant Additional Information:		Description: advisory board
Miltenyi Biotec	Other	Self
Category: Other Additional Information: to institutiion		Description: Scientific Advisory Board
Novartis Pharma	Other	Self
Category: Other Additional Information:		Description: travel reimbursement investigator meeting
Novartis Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: advisory board
Novartis Pharma	Consultant	Other - fee paid to institution
Category: Consultant Additional Information:		Description: advisory board
Novartis Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: advisory board
Novartis Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: speaker fee
Takeda Oncology	Consultant	Self
Category: Consultant Additional Information: Scientific Advisory Board Fee paid to Institution		Description:

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Daiichi Sankyo Company	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board/Consultancy

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2. What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Amgen	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Astellas Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Bayer	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
BeiGene, Ltd.	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Bristol-Myers Squibb	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Celgene	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Janssen Biotech	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Merck	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Roche Products Limited	Consultant	Self
Category: Consultant Additional Information:		Description: consultant
Takeda Oncology	Consultant	Self
Category: Consultant Additional Information:		Description: consultant

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2.

What is the manuscript title?
Tisagenlecleucel versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Astellas Pharma	Consultant	Self
Category: Consultant Additional Information:		Description:
Bristol-Myers Squibb	Grant / Contract	Self
Recipient Name: joaquin martinez Grant / Contract Description: CNIO Additional Information:		Recipient Type: Individual Grant / Contract Purpose: Research
F. Hoffmann-La Roche	Consultant	Self
Category: Consultant Additional Information:		Description:
Janssen Biotech	Consultant	Self
Category: Consultant Additional Information:		Description:
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description:

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Employment	Self
Title: Global Program Clinical Head Additional Information:		Position Description: Executive medical director

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2. What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Artiva bio	Consultant	Self
Category: Consultant Additional Information:		Description:
Celgene Corporation	Consultant	Self
Category: Consultant Additional Information:		Description:
CRISPR therapeutics	Consultant	Self
Category: Consultant Additional Information:		Description:
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description:

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AlloVir	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board
Bristol-Myers Squibb	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board
Kite Pharma, Inc.	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description: speaker

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences Inc	Consultant	Self
Category: Consultant Additional Information:		Description: Speaker bureau, consultant for Gilead and Kite

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Alnylam Pharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> paid to employer		<i>Description:</i> advisory committee
Bristol-Myers Squibb	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Lecture
Celgene Corporation	Travel	Self
<i>Location(s):</i> congress ASH <i>Additional Information:</i>		<i>Purpose:</i> hospitality
Gilead Sciences	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> paid to employer		<i>Description:</i> Training to european colleagues
Johnson & Johnson Health Care Systems Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> to employer		<i>Description:</i> training AL amyloidosis

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol-Myers Squibb	Other	Self
Category: Other Additional Information:		Description: Advisory Boards
Gilead Sciences	Other	Self
Category: Other Additional Information:		Description: Speaker's Honoaria
Janssen Biotech	Other	Self
Category: Other Additional Information:		Description: Speaker's honoraria
Janssen Biotech	Other	Self
Category: Other Additional Information:		Description: Advisory Board
Novartis	Consultant	Self
Category: Consultant Additional Information: 4 sessions, 1hr each, hourly rate		Description: expert consultancy
Novartis	Other	Self
Category: Other Additional Information: hourly rate		Description: National Advisory Boards 17.12.2020

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Other	Self
Category: Other Additional Information:		Description: advisory board
Bristol Myers Squibb Company	Other	Self
Category: Other Additional Information:		Description: advisory boards
Epizyme, Inc.,	Other	Self
Category: Other Additional Information:		Description: Advisory board
F. Hoffmann-La Roche AG	Consultant	Self
Category: Consultant Additional Information:		Description: consultant on management non hodgkin lymphoma
F. Hoffmann-La Roche AG	Expert Witness	Self
Category: Expert Witness Additional Information:		Description: expert testimony
F. Hoffmann-La Roche AG	Expert Witness	Self
Category: Expert Witness Additional Information:		Description: expert testimony
F. Hoffmann-La Roche AG	Other	Self
Category: Other Additional Information:		Description: advisory boards and scientific lectures
Gilead Sciences Inc	Other	Self
Category: Other Additional Information:		Description: advisory board
Johnson and Johnson	Other	Self
Category: Other Additional Information:		Description: advisory board and scientific lecture
Novartis	Other	Self
Category: Other Additional Information:		Description: advisory board

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Novartis	Employment	Self
Title: Senior Principal Biostatistician Additional Information:		Position Description:

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol Myers Squibb Company	Other	Self
<i>Category:</i> Other <i>Description:</i> Payment for participation in advisory board. Payment was made directly to my institution. <i>Additional Information:</i> Payment was made directly to my institution (Fiona Stanley Hospital) for research and education only and no payment was made directly to myself.		
Gilead Sciences	Other	Self
<i>Category:</i> Other <i>Description:</i> Participation in advisory board <i>Additional Information:</i> Payment for this role was made directly to my institution (Fiona Stanley Hospital) for education and research purposes. No payment received by myself.		
Novartis	Other	Self
<i>Category:</i> Other <i>Description:</i> Advisory board <i>Additional Information:</i> Payment for this role was made directly to my institution (Fiona Stanley Hospital) and is available for general education and research purposes by the department of haematology. No payment received by myself.		

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Tisagenlecleucel Vrsus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Consultant	Self
Category: Consultant Additional Information:	Description:	
AstraZeneca	Consultant	Self
Category: Consultant Additional Information:	Description:	
BeiGene USA, Inc.	Consultant	Self
Category: Consultant Additional Information:	Description:	
Celgene Corporation	Consultant	Self
Category: Consultant Additional Information:	Description:	
Genentech	Grant / Contract	Self
Recipient Name: University of Pennsylvania Grant / Contract Description: Additional Information:	Recipient Type: Institution Grant / Contract Purpose: Research	
Genentech	Consultant	Self
Category: Consultant Additional Information:	Description:	
Incyte Corporation	Consultant	Self
Category: Consultant Additional Information:	Description:	
Janssen Biotech, Inc.	Consultant	Self
Category: Consultant Additional Information:	Description:	
Legend Biotech	Consultant	Self
Category: Consultant Additional Information:	Description:	
Loxo Oncology	Consultant	Self
Category: Consultant Additional Information:	Description:	
Merck	Grant / Contract	Self
Recipient Name: University of Pennsylvania Grant / Contract Description: Additional Information:	Recipient Type: Institution Grant / Contract Purpose: Research	
Novartis	Consultant	Self
Category: Consultant Additional Information:	Description:	
Regeneron Pharmaceuticals, Inc.	Consultant	Self
Category: Consultant Additional Information:	Description:	

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bristol-Myers Squibb Company	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Boards, Continuous Education
Gilead Sciences Inc	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Boards, Continuous Education
Janssen Global Services, LLC	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board
Merck Sharp & Dohme Corporation	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Boards, Continuous Education
Novartis Pharma	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Boards, Continuous Education
SANOFI US SERVICES INC.	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board, Continuous Education Programs
Takeda Oncology	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Boards, Continuous Education Program

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Celgene	Consultant	Self
Category: Consultant Additional Information:		Description:
Gilead Foundation	Consultant	Self
Category: Consultant Additional Information:		Description:
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description:

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2. What is the manuscript title?

Tisagenlecleucel versus standard of care in second-line aggressive B-cell lymphoma
3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16596

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
ADC Therapeutics	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Amgen	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
AstraZeneca	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Bristol-Myers Squibb	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Genentech	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Genmab	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Iksuda Therapeutics	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Incyte Corporation	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Janssen Biotech	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Karyopharm Therapeutics	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Kite Pharma, Inc.	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Merck	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	
Monta Rosa Therapeutics	Consultant	Self
Category: Consultant Additional Information:	Description: Advisory Board	

Morphosys	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board
Novartis	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board
Umoja Biopharma, Inc.	Consultant	Self
Category: Consultant Additional Information:		Description: Advisory Board

Additional Questions:

1.

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.
2.

What is the manuscript title?

Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma
3.

Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.